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Serum-derived extracellular 
vesicles (EVs) impact on vascular 
remodeling and prevent muscle 
damage in acute hind limb ischemia
Claudia Cavallari1, Andrea Ranghino1, Marta Tapparo1, Massimo Cedrino1, Federico Figliolini1, 
Cristina Grange1, Valentina Giannachi1, Paolo Garneri2, Maria Chiara Deregibus1, Federica 
Collino1, Pietro Rispoli2, Giovanni Camussi1 & Maria Felice Brizzi  1
Serum is an abundant and accessible source of circulating extracellular vesicles (EVs). Serum-EV (sEV) 
pro-angiogenic capability and mechanisms are herein analyzed using an in vitro assay which predicts 
sEV angiogenic potential in vivo. Effective sEVs (e-sEVs) also improved vascular remodeling and 
prevented muscle damage in a mouse model of acute hind limb ischemia. e-sEV angiogenic proteomic 
and transcriptomic analyses show a positive correlation with matrix-metalloproteinase activation and 
extracellular matrix organization, cytokine and chemokine signaling pathways, Insulin-like Growth 
Factor and platelet pathways, and Vascular Endothelial Growth Factor signaling. A discrete gene 
signature, which highlights differences in e-sEV and ineffective-EV biological activity, was identified 
using gene ontology (GO) functional analysis. An enrichment of genes associated with the Transforming 
Growth Factor beta 1 (TGFβ1) signaling cascade is associated with e-sEV administration but not 
with ineffective-EVs. Chromatin immunoprecipitation analysis on the inhibitor of DNA binding I (ID1) 
promoter region, and the knock-down of small mother against decapentaplegic (SMAD)1–5 proteins 
confirmed GO functional analyses. This study demonstrates sEV pro-angiogenic activity, validates 
a simple, sEV pro-angiogenic assay which predicts their biological activity in vivo, and identifies the 
TGFβ1 cascade as a relevant mediator. We propose serum as a readily available source of EVs for 
therapeutic purposes.
Critical limb ischemia (CLI), the most severe consequence of peripheral artery disease, is a rife condition caused 
by acute occlusion of the peripheral arteries1. Although surgical or endovascular intervention are still the stand-
ard therapy for improving blood flow2, most patients complain of persistent or recurring symptoms even after 
successful revascularization3. This implies that new therapeutic options for patients complying these symptoms 
are very much still a major unmet need.
The formation of newly born capillary blood vessels, neovascularization, is a crucial event in rescuing tissue 
after ischemia. A vast array of pre-clinical and clinical data indicates that stem cells can contribute to the heal-
ing processes by improving vascularization4, 5. However, the transient detection of stem cells at the site of tissue 
damage has suggested that paracrine mechanisms may contribute to stem cell action6, 7. “Exosomes”, vesicles 
derived from the endosomal membrane compartment by exocytosis, and “ectosomes/microvesicles”, vesicles gen-
erated by the budding of cell plasma membranes8 are included among such paracrine mechanisms. Due to the 
overlap in the characteristics and biological activity of exosomes and ectosomes/microvesicles9, it has recently 
been suggested that a more inclusive term, “extracellular vesicles” (EVs), be used. EVs are powerful cell-to-cell 
communication mediators in both physiological and pathological conditions10. Recent studies have provided evi-
dence that the transfer of EV cargo can dictate recipient cell fate11, 12. Indeed, the transfer of EV cargo, including 
nucleic acids and proteins, into recipient cells is the most relevant mechanism of EV action13, 14. The most studied 
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EVs are currently those released by stem cells, thanks to their ability to mimic the effects of the cell of origin14. 
A range of different phenotypic changes, depending on the pathological setting, have been described in target 
cells15. Transcriptomic and proteomic analyses have often been performed in an attempt to try to characterize 
EV mechanism of action11, 16. In particular, a robust pro-angiogenic profile has been described in EVs recovered 
from mesenchymal stem cells derived from bone marrow or adipose tissues5, 17. These observations have hinted 
at the potential impact of EVs in clinical settings, including ischemia-related diseases18, 19. The relevance of EVs 
in physiological and pathological angiogenesis and their mechanisms of action have been extensively reviewed 
by Kholia et al.20.
EVs that have been physiologically released from several cell types can be detected in biological fluids, includ-
ing blood21–24. The EVs present in blood could therefore be an important resource for regenerative medicine. 
Indeed, plasma EVs have been reported to provide a cardioprotective effect against ischemia-reperfusion injury25. 
Experiments into the depletion of EVs in fetal bovine serum have displayed an impaired ability to induce muscle 
cell proliferation and differentiation26, suggesting that serum EVs (sEVs) possess defined biological properties.
The aim of the present study was to mechanistically investigate the angiogenic potential of EVs that had been 
purified from the sera of healthy donors (sEVs). In particular, the possible therapeutic impact of sEVs in inducing 
angiogenesis and improving the reperfusion of acute hind limb ischemia has been investigated. Moreover, an 
mRNA-angiogenesis microarray has been performed on endothelial cells (ECs) recovered from capillary-like 
structures formed in response to sEVs in order to dissect their mechanism(s) of action.
Results
Characterization and functional activity of sEVs. All EV samples were analyzed for their surface 
antigens via Guava FACS analysis. As expected, it was demonstrated that sEVs are heterogeneous due to their 
differing cells of origin (platelets, endothelial cells, monocytes/leukocytes) (Supplementary Table S1). The sEV 
expression of cell adhesion markers was also detected (Supplementary Table S1). Nanosight analyses did not 
bring to light any significant differences in sEV number and size among the samples. The number of sEVs recov-
ered from a bag of 110 ml was around 6.16 × 108 particles/ml (Supplementary Fig. S1), while sEV diameter was 
approximately 210 nm with a modal particle size of 183 nm (Supplementary Fig. S1). Starting from 2 × 1011 of 
total particles, the recovery of sEV RNA and protein was similar in all samples analyzed (n = 18), and ranged 
from 300 to 500 ng of RNA and 1 to 1.2 µg of protein (Supplementary Fig. S1). To avoid possible contamination of 
non-sEV-associated mRNAs and proteins, floating density gradient was used to separate sEVs27, 28. The expression 
of the CD63 exosomal marker was also detected, using Western Blot (WB) analysis, in the 30% iodixanol floating 
fraction (see Methods) (Supplementary Fig. S2).
In order to try and predict the pro-angiogenic activity of sEVs, an in vitro assay was performed using VEGF 
as the internal control. Effective sEVs (e-sEVs) were considered to be those demonstrating almost 50% of VEGF 
proangiogenic activity when analyzed for their ability to induce ECs proliferation and tube-like structure forma-
tion. As shown in Table 1, 14 out of 18 sEV samples displayed such a feature.
sEVs
Angiogenesis 
assay %
Proliferation 
assay % Average % Results
1 42.8 ± 1.4 62.5 ± 2.3 52.6 ± 1.9 e-sEV
2 54.4 ± 3.9 56.4 ± 3.1 55.4 ± 3.5 e-sEV
3 31.9 ± 1.4 89.5 ± 0.5 60.7 ± 1.0 e-sEV
4 53.3 ± 0.3 64.1 ± 1.1 58.7 ± 0.7 e-sEV
5 68.7 ± 2.6 55.5 ± 3.1 62.1 ± 2.9 e-sEV
6 43.8 ± 0.9 77.6 ± 4.0 60.7 ± 2.5 e-sEV
7 88.5 ± 4.2 66.2 ± 3.3 77.4 ± 3.8 e-sEV
8 65.5 ± 0.6 44.4 ± 0.5 54.9 ± 0.6 e-sEV
9 56.5 ± 4.5 50.1 ± 3.9 53.3 ± 4.2 e-sEV
10 31.5 ± 1.1 99.8 ± 5.6 65.7 ± 3.4 e-sEV
11 35.2 ± 8.3 8.5 ± 4.1 21.9 ± 6.2 i-sEV
12 99.2 ± 0.5 32.2 ± 3.4 65.7 ± 2.0 e-sEV
13 28.8 ± 3.2 24.5 ± 2.3 26.7 ± 2.8 i-sEV
14 41.7 ± 6.6 68.6 ± 4.5 55.2 ± 5.6 e-sEV
15 50 ± 3.8 55 ± 4.9 52.5 ± 4.4 e-sEV
16 8.3 ± 1.3 19.1 ± 4.0 13.7 ± 2.5 i-sEV
17 66.7 ± 4.5 41.1 ± 4.2 53.9 ± 6.6 e-sEV
18 15.1 ± 1.5 3.6 ± 0.6 9.5 ± 2.6 i-sEV
Table 1. Proangiogenic in vitro effects of different sEV samples. 18 sEV samples evaluated by in vitro 
angiogenesis assay and in vitro proliferation assay on ECs. The average represents the mean value of results of 
both assays ± SD (see Methods). sEVs with an average value exceeding 50% have been considered effective sEVs 
(e-sEVs) otherwise they are ineffective (i-sEVs).
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sEVs induce in vitro and in vivo angiogenesis. A comparison of in vitro and in vivo experiments was 
performed in order to validate the predicted sEV pro-angiogenic activity. The in vitro tridimensional angiogenic 
assay was used to analyze four distinct samples for both e-sEVs and ineffective s-EVs (i-sEVs). As shown in 
Fig. 1A, e-sEVs were able to induce tube-like structure formation in vitro, unlike i-sEVs. In order to verify these 
results in vivo, selected sEVs were used in SCID mice. ECs treated with effective and ineffective sEVs (5 × 104 
sEV/cell) and mixed with Matrigel were injected subcutaneously into SCID mice for this purpose. Matrigel plugs 
were removed and analyzed after one week. As shown in Fig. 1B, only e-sEVs displayed pro- angiogenic activity in 
vivo. These data indicate that our in vitro assays were able to predict sEVs pro-angiogenetic capability.
sEVs improve reperfusion recovery and prevent muscle damage after ischemia. e-sEVs were also 
evaluated in a murine model of acute ischemic hind limbs that mimics CLI in humans. A total amount of 2 × 1010 
e-sEVs was administrated after surgery (see Methods). Different routes of i-sEV and e-sEV administration were 
assayed in order to evaluate their therapeutic potential (data not shown). The best response, was obtained as fol-
lows: intravenous injection immediately after surgery (T0) and intramuscular at T1 and T2. This approach was 
used throughout the study. Blood perfusion in the ischemic hind limb, as evaluated by Laser Doppler Perfusion 
imaging immediately after surgery, demonstrated that the ratio between the ischemic and non-ischemic hind 
limbs decreased in all groups (0.13 ± 0.06 control group; 0.12 ± 0.04 in e-sEV group; and 0.11 ± 0.02 in i-sEV 
group) (Fig. 2). With the limitation of this approach, which does not allow quantification of deep vascular dis-
tricts29, 30, we found that e-sEVs, but not i-sEVs and vehicle-treated animals, displayed a significant increased 
hind limb perfusion ratio at day 7 after surgery (e-sEVs 0.89 ± 0.26 vs control 0.6 ± 0.18 and vs i-sEVs 0.46 ± 0.13, 
p < 0.05) (Fig. 2B). Functional score applied to all groups demonstrated that the damage was also significantly 
higher in vehicle and i-sEV-treated groups than in the e-sEV-treated group (Fig. 2C)19, 31. Consistently, capillary 
density in the ischemic hind limbs was significantly increased in e-sEV-group of animals (vessel number/HPF: 
e-sEVs 22.4 ± 5.5 vs control 11.2 ± 1.8 and vs i-sEVs 11.68 ± 3.7, p < 0.05) (Fig. 3). The analysis of the gastroc-
nemius muscles of either i-sEVs and vehicle-treated animals revealed the presence of focal areas of necrosis and 
inflammation (Figs 3 and 4). CD14 positive cells and polymorph-nuclear cells were also detected in vehicle and 
i-sEVs-treated mice (Fig. 4). The necrosis and infiltrate of inflammatory cells were almost completely prevented 
by e-sEV administration (Fig. 4). Finally, even if at day 7 in vehicle and i-sEV-treated animals the capillary density 
was improved in respect to day 1 (not shown), it was not sufficient to prevent muscle damage.
e-sEV-cargo analysis. The above results led us to investigate how angiogenic-related mRNAs and proteins 
contribute to e-sEV biological activity. According to an mRNA and protein microarray analysis (Supplementary 
Table S2), we selected the first 11 angiogenic mRNAs and proteins expressed by e-sEVs (Fig. 5A). TGFβ1 was 
commonly detected when mRNA and protein in e-sEVs was compared. The presence of TGFβ1 was also vali-
dated by real time-PCR (RT-PCR) and WB analyses (Fig. 5B). Moreover, as shown in Fig. 5B, TGFβ1 mRNA and 
protein were almost undetectable in i-sEVs. TGFβ1, mRNA and protein were also found when a density gradient 
(OptiPrep) (27) was used to isolate e-sEVs (Supplementary Fig. S2). By cross-matching e-sEV transcripts and 
proteins significant positive correlations with the activation of matrix metalloproteinases and extracellular matrix 
organization (p-value = 9.17 × 10−6), the cytokine and chemokine signaling pathways (p-value = 4.7 × 10−6), IGF 
and platelet pathways (p-value = 5.03 × 10−5), the VEGF signaling pathway (p-value = 3.49 × 10−4) were detected 
(Fig. 5C).
e-sEV treatment activates a specific gene signature. In order to explore the mechanisms that account 
for e-sEV biological activity, an mRNA-angiogenesis microarray analysis was performed on ECs recovered from 
capillary-like structures formed in response to e-sEVs and i-sEVs. VEGF was used as a positive control. A dis-
crete pattern of modulated genes emerged when e-sEV and i-sEV treatments were compared (Supplementary 
Tables S3 and S4 for each treatment and Table S5 for comparison between treatments). In particular, we found 
that 43 genes up-regulated (out of 84 analysed genes) upon e-sEV treatment were down-regulated upon i-sEV 
treatment (see Supplementary Table S5 and Fig. 6A). These data identify a specific gene signature, associated 
with e-sEVs, which supports divergence from i-sEV biological effects (Fig. 6A). We also compared the pattern 
of overexpressed genes activated in response to e-sEVs and VEGF (Supplementary Table S6) and found that, 
although the pro-angiogenic effects exerted by e-sEV and VEGF treatments were almost comparable, a different 
pattern of gene expression was noted. A Venn diagram, reported in Supplementary Fig. 3A, indicates the genes 
commonly modulated by these treatments. Gene Ontology (GO) was carried out, using DAVID GO-based func-
tional analysis, on overexpressed transcripts (only transcripts with a fold increase values ≥3 were considered, see 
Supplementary Table S3) to dissect the molecular events associated with e-sEV treatment. As shown in Fig. 6B, an 
enrichment of genes associated with the TGFβ1 signaling pathway was found upon e-sEV treatment. As a matter 
of fact, the most representative clusters of genes activated in response to e-sEVs, but not i-sEVs, consist of genes 
involved in the ALK1 signaling pathway (Fig. 6C). These latter results further substantiate the transcriptomic 
analysis (Supplementary Table S3) which identified the inhibitor of DNA binding I (ID1) as one of the most highly 
expressed genes. Finally, GO functional analysis identified a diverse cluster of genes and related biological path-
ways (Supplementary Fig. S3) which is consistent with differences in the gene expression profile associated with 
VEGF and e-sEV treatment.
e-sEV treatment leads to the formation of a SMAD1–5 transcriptional complex which binds 
the ID1 promoter. It is widely recognized that the engagement of small mother against decapentaplegic 
(SMAD)1–5 by ALK1 is a crucial step for TGFβ1-mediated angiogenesis32. The activation of SMAD1–5 was 
therefore analyzed in ECs treated with sEVs and compared to TGFβ1 to further confirm the GO analysis. As 
shown in Fig. 7A, rapid and transient SMAD1–5 phosphorylation occurred upon TGFβ1 treatment. By contrast, 
www.nature.com/scientificreports/
4Scientific REPORTS | 7: 8180  | DOI:10.1038/s41598-017-08250-0
Figure 1. In vitro and in vivo angiogenesis in response to sEVs. (A) In vitro quantitative analysis of the % of 
vessel-like structures formed (tubulogenesis assay) in response to the indicated stimuli. Untreated ECs was the 
negative control, VEGF (10 ng/ml) was the positive control, while e-sEVs (samples # 12, 14, 15, 17) and i-sEVs 
(samples # 11, 13, 16, 18) were the stimuli. (Original magnification: ×200; scale bar: 500 μm). (B) In vivo  
quantitative analysis of vessels counted in 10 sections of matrigel for each experimental condition. Data 
represent the mean value of untreated (C) (n = 6) or treated mice with: VEGF (n = 6), e-sEVs (samples # 12, 
14, 15, 17) (n = 6 each sample) and i-sEVs (samples # 11, 13) (n = 6 each sample). ECs (red), erythrocytes 
(yellow) and matrigel (light blue) staining in matrigel plugs. Images above the graphs are representative of each 
condition. (Original magnification: ×20). Arrows indicate vessels. *p < 0.05; **p < 0.01, (One-way ANOVA 
followed by Tukey’s post hoc test). (Original magnification: ×200; scale bar: 12 μm).
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e-sEV treatment led to delayed SMAD1–5 phosphorylation picking at 4 hours. It is worth noting that no 
SMAD1–5 phosphorylation was detected when i-sEVs were used. We thus sought to evaluate SMAD1–5 tran-
scriptional activity on the ID1 promoter. A chromatin immunoprecipitation (ChIP) analysis was performed, for 
this purpose, using both e-sEVs and i-sEVs. As shown in Fig. 7B, only e-sEVs were able to induce the formation 
of a SMAD1–5 transcriptional complex which binds to the ID1 promoter, which is consistent with SMAD1–5 
phosphorylation. siRNA technology was also used to confirm these data (Supplementary Fig. S4). As shown in 
Fig. 7B, SMAD1-5 knock-down abolished e-sEV-mediated SMAD1-5 transcriptional complex formation as well 
as binding to the ID1 promoter. This resulted in the inhibition of e-sEV-mediated tube-like structure formation 
(Fig. 7C).
Discussion
EVs, that were first described decades ago33, have more recently attracted particular attention because their par-
acrine and endocrine action have been recognized34. Stem cell-derived EVs are the most studied EVs20, 35 as 
they possess the vast potential to impact upon both tissue engineering and regenerative medicine. EV biological 
activity has been linked to the transfer of bioactive lipids, proteins, receptors, mRNAs and miRNAs that may 
change the phenotype and function of recipient cells36–38. However, the past two decades have seen EVs also being 
detected in body fluids23, 24 serum which are easily accessible sources of EVs that are derived from different cell 
types21, 39. Data obtained by clinical studies revealed that about 80% of circulating EVs derive from platelets40. 
Although all cell types are able to release EVs13, 41, it has been reported that only a small subpopulation of circulat-
ing EVs are of endothelial origin42. We herein demonstrate that serum from healthy donors contains EVs which 
mainly express endothelial and platelets markers and, more importantly, display pro-angiogenic potential both 
in vitro and in vivo. In vivo, this is particularly evident from the analysis of capillary density which demonstrated 
that e-sEVs led to a doubling of the capillary density as compared to normal, while data from the Laser Doppler 
perfusion are less evident because this technique does not allow detection of profound vascular districts. Based 
on a functional in vitro “potency assay”, we identified a set of biologically active and inactive sEVs and were able 
to predict their in vivo angiogenic potential. Moreover, it has been shown herein that e-sEVs improved large ves-
sel reperfusion and protected muscle from ischemia-induced damage in a preclinical model of acute hind limb 
ischemia. This data add further to the role of serum-derived exosomes described in the ischemia-reperfusion 
heart model25.
It is known that a number of soluble factors are released locally and actively participate in muscle regener-
ation after ischemia in vivo43, 44. In particular, IGF1 has been shown to contribute to this process in vivo45. In 
this work, proteomic analysis has demonstrated that e-sEVs are enriched in IGF1 and network analyses have 
revealed a significant positive correlation with the IGF pathway. No necrotic areas were found in the ischemic 
muscles of e-sEV-treated mice. This suggests that e-sEV treatment, rather than inducing regenerating signals to 
damaged muscles, is able to rapidly improve vascular remodeling and protect muscles against ischemia-induced 
tissue injury. Indeed, it has been extensively reported that one of the important components for tissue repair 
is the formation of new blood vessels46. Several studies have described the contribution of EVs, released from 
different stem cells types, in promoting angiogenesis18, 37, while miRNAs, mRNA and protein carried by EVs 
have been implicated in this process20, 47. Besides stem cells, platelet-derived EVs have also been reported to pro-
mote proliferation, survival, migration and the formation of capillary-like structures in vitro48 and angiogenesis 
in ischemic rat hearts in vivo49. However, answers to how EVs play a part in intercellular communication and 
how sEVs concomitantly contribute to target cell biological response are still not forthcoming and remain major 
challenges for the future. We herein demonstrate that e-sEVs are enriched in angiogenic modulators, in terms of 
Figure 2. e-sEVs increase blood perfusion and reduced damage in ischemic hind limbs. (A) Representative 
images of Laser Doppler Blood Flow (LDBF) obtained prior (pre-surg) and immediately after intervention 
(T0) and at day 7 after surgery (T7) of mice treated with Vehicle, with e-sEVs and i-sEVs. (B) Quantitative 
analysis of blood perfusion measured by LDBF. Data are expressed as mean ± SD; *p  < 0.05 (One-way ANOVA 
- Newman-Keuls Multiple Comparison Test) (n = 10). (C) Foot damage score was evaluated for the indicated 
times as reported in Methods. Data are expressed as mean ± SEM, n = 10 (*p < 0.05 ischemic limb of e-sEVs 
mice vs ischemic limb of vehicle and i-sEVs mice).
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both proteins and mRNAs. Moreover, database analysis demonstrates that TGFβ1 was expressed as mRNA and 
protein in e-sEVs, suggesting that TGFβ1 signaling may be relevant in inducing a fast angiogenic switch, resulting 
in muscle protection against ischemia-reperfusion damage in our preclinical model.
Several data indicate that the biological response of ECs to TGFβ1 might be either stimulatory or inhibitory, 
depending on the cell status and on microenvironment-mediated stimuli50. TGFβ1 signaling is initiated by bind-
ing to the constitutively active type II serine-threonine kinase receptor which, in turn, recruits and phosphoryl-
ates the type I receptor, the so called activin receptor-like kinese 5, ALK532. ALK5 is the most widely expressed 
receptor. However, at sites of active angiogenesis51, ECs highly express a different type I serine-threonine kinase 
receptor, denoted ALK150. The co-expression of both ALK1 and ALK5 led to the enrollment of varying SMAD 
family members; SMAD1–5 for ALK1 and SMAD2–3 for ALK532. As the result of such differential activation, 
discrete target gene regulation takes place and leads to a variety of biological effects52. In fact, ALK5 inhibits EC 
migration in vitro53 and angiogenesis in vivo54 by inducing the expression of fibronectin and the plasminogen 
activator inhibitory type I (PAI-1), while ALK1 induces cell cycle progression by controlling the expression of 
ID155, 56. It is worth noting that a comparison of GO functional analyses between e-sEV and i-sEV-treated cells 
revealed a specific gene signature, which relies on the TGFβ1-mediated pathway, that supports the role of TGFβ1 
in the e-sEV mechanism of action. As a proof of concept, e-sEV treatment, but not i-sEV, led to SMAD1–5 phos-
phorylation and the formation of a SMAD1-5 transcriptional complex which bound to the ID1 promoter, while 
SMAD1-5 knock down prevented ID1 gene transcription and e-sEV-mediated tube-like structure formation. 
Figure 3. e-sEVs increase capillary density and protect muscle from ischemic damage. (A) Representative 
hematoxylin-eosin images of gastrocnemius muscles of non-ischemic (Normal hind limb) and ischemic hind 
limb of Vehicle, e-sEVs and i-sEVs treated animals (Original Magnification: ×200; scale bar: 50 µm), (upper 
panels). Representative immunofluorescence images (confocal microscopy) of capillary density staining. An 
anti-CD31 mAb was used to analyze gastrocnemius muscles of non-ischemic (Normal hind limb) and ischemic 
hind limbs as indicated (Original Magnification: ×400; scale bar: 25 µm) (lower panels). (B) Quantitative 
analysis of muscle damage areas in hematoxilin-eosin stained gastrocnemius muscles of normal and ischemic 
hind limbs at day 7 after surgery. e-sEVs significantly reduce muscle damage compared to Vehicle. Data 
are expressed as mean ± SEM; *p  < 0.05 e-sEVs vs Vehicle, (One-way ANOVA - Newman-Keuls Multiple 
Comparison Test), (left panel) (n = 10). Quantitative analysis of capillary density of normal and ischemic hind 
limbs at day 7 after surgery indicates that e-sEVs significantly increase capillary density compared to Vehicle. 
Data are expressed as mean ± SEM; *p < 0.05, e-sEVs vs Vehicle, (One-Way ANOVA - Newman-Keuls Multiple 
Comparison Test), (right panel).
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Further to these observations, GO functional analyses revealed an enrichment in the genes involved in the ALK1 
pathway and linked to the activation phase of angiogenesis, but only in cells treated with e-sEVs.
The results provided herein therefore support the possibility that the e-sEV-mediated activation of the TGFβ1/
ALK1/ID1 cascade may provide a fine tuning angiogenic response which balances the vascular remodeling pro-
cess and protects muscles against ischemia-induced damage. This would be particularly relevant if e-sEVs could 
be exploited in a clinical setting, such as CLI. Indeed, CLI is considered the leading cause of non-traumatic 
amputations in the western world and brings with it a significant health burden globally. Surgical and endovas-
cular treatments are currently considered to be the front-line in avoiding limb loss in humans57, however the 
recurrence of symptoms is a common problem58. Alternative treatment options are still limited also for patients 
to whom surgery has failed to improve long-term outcomes59. Clinical trials, including VEGF-A administration 
for therapeutic angiogenesis, have not been successful60. The establishment of a fine balance between VEGF and 
additional pro-angiogenic/stabilization pathways has recently been suggested as a means to improve the forma-
tion of a functional vascular network61. Interestingly, a different pattern of gene expression was found when GO 
functional analyses in VEGF and e-sEV treated cells were compared. One may speculate that e-sEVs and VEGF 
could become an alternative combined treatment with which to improve the formation of a functional vascular 
network. However, the positive correlation with the VEGF signaling pathway that was detected by cross-matching 
e-sEV transcripts and proteins means that e-sEVs may theoretically already be able to exert such a combinatory 
effect by themselves.
Overall, we have shown that EVs displaying pro-angiogenic potential can be obtained from the serum of 
healthy donors. We have identified a simple in vitro test to predict serum-EV angiogenic potential in vivo. The 
GO-based functional analysis of ECs recovered from the capillary-like structures formed in response to i-sEVs 
and e-sEVs have identified a gene signature which sheds light on their varying biological activity. Finally, we have 
identified the TGFβ1/ALK1/ID1 cascade as the most relevant mechanism for e-sEV biological activity, which is 
consistent with data obtained from the GO functional analysis. More importantly, our data provide the scientific 
rationale for the use of sEVs as an alternative therapeutic option for vascular remodeling, better local perfusion 
and protection against muscle damage in patients with acute hind limb ischemia.
Methods
Study approval. Animal studies were conducted in accordance with the Italian National Institute of Health 
Guide for the Care and Use of Laboratory Animals. All procedures were approved by the Ethics Committee of 
the University of Turin and the Italian Health Ministry (authorization number:490/2105-PR). Mice were housed 
according with the Federation of European Laboratory Animal Science Association Guidelines. All experiments 
were performed in accordance with relevant guidelines and regulations.
Vesicle isolation and characterization. Human serum from healthy blood donors (n = 18) was provided 
by the Blood Bank of “Città della Salute e della Scienza di Torino”, after informed consent and approval by the 
internal Review Board of the Blood Bank. Informed consent was obtained by the Blood Bank of “Città della Salute 
Figure 4. Inflammatory infiltrate in ischemic hind limb. (A) Representative hematoxylin-eosin images of 
gastrocnemius muscles of non-ischemic (Normal hind limb) and ischemic hind limbs of Vehicle, e-sEVs 
and i-sEVs treated animals (Original Magnification: ×400; scale bar: 25 µm), showing mononuclear and 
polymorphonuclear cells. (B) Representative immunofluorescence images of gastrocnemius muscles, stained 
with an anti CD14 antibody (Original Magnification: ×400; scale bar: 25 µm). (C) Quantitative analysis of 
muscle damage areas in hematoxylin-eosin stained gastrocnemius muscles of the normal and ischemic hind 
limbs at day 7 after surgery. e-sEVs significantly reduce the number of inflammatory cells compared to the 
control (vehicle). Data are expressed as mean ± SEM; *p < 0.05, e-sEVs vs Vehicle, (One-Way ANOVA - 
Newman-Keuls Multiple Comparison Test) (n = 6).
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e della Scienza di Torino” from all participants. sEVs from each donor were obtained from 110 ml serum bags. 
Details are reported in (Supplementary Information).
Floating density gradient separation. Floating density separation on iodixanol (Optiprep from Sigma) 
was modified, from Kowal et al.28, in order to obtain larger centrifugation volumes with sufficient amounts of 
e-sEVs for functional studies. Details are reported in (Supplementary Information). 35 ng of proteins were loaded 
for the WB analysis. Supersignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, Rockford, 
IL, USA) was used for detection. 3 ng of total RNA was used for the RT-PCR analysis. Details are reported in 
(Supplementary Information).
Figure 5. e-sEV angiogenic mRNA and protein content. (A) Venn diagram to show the first 11 angiogenic 
mRNAs and proteins expressed by e-sEVs. TGFβ1 was commonly detected as mRNAs and proteins. Data were 
analyzed by Funrich V3 tool. (B) RT-PCR was used to detect TGFβ1 mRNA in e-sEV cargo. RT-PCR data 
are expressed as relative quantification (RQ) ± SD (*p < 0.05) (n = 4). (C) e-sEV were analyzed by Western 
Blot analysis for TGFβ1 content and normalized to CD63 (n = 4) (***p < 0.001). Mesangial cells were used 
as positive control (+). (D) Network analysis of pathways positively correlated with e-sEV transcripts and 
proteins. Pathways positively correlated are reported in the boxes. Data were obtained by GeneMANIA analysis 
performed on Cytoscape.
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Guava FACS analysis and Nanoparticle tracking analysis. sEV FACS analysis was performed using 
a Guava easyCyte™ Flow Cytometer (Millipore, Germany) as previously described5, 62. Specific cell markers were 
used. sEVs were also analyzed using the Nanosight LM10 system (Nanosight Ltd., Amesbury, UK) as previously 
described62. Details are reported in (Supplementary Information).
sEV angiogenic assay. In preliminary studies, a dose response curve was performed to evaluate the number 
of sEVs needed to obtain the best biological response in human microvascular endothelial cells (HMEC)5. The 
acronym ECs will be used throughout the study. It was found, using 4 different sEV samples, that 5 × 104 sEVs/
target cells was the most effective sEV dose. 5 × 104 sEVs/target cells were therefore used throughout the in vitro 
study63. sEVs from single samples were thus evaluated for their pro-angiogenic activity using BrdU64 and in vitro 
tubulogenesis assays37. Negative and positive controls were used to evaluate sEVs angiogenic potency (for BrdU 
Figure 6. Gene pattern and representative biological pathways associated with e-sEV and i-sEV administration. 
(A) Representative Venn diagram of up-regulated and down-regulated mRNA in ECs treated with e-sEVs and 
i-sEVs. 43 genes up-regulated after e-sEV treatment were down-regulated upon i-sEV treatment; 12 genes 
down-regulated after e-sEV treatment were up-regulated after i-sEV treatment; 20 genes up-regulated upon 
e-sEV treatment were up-regulated upon i-sEV treatment and 9 genes down-regulated after e-sEV treatment 
were down-regulated upon i-sEV treatment. The list of genes is reported in Supplementary Table S4. (B) GO 
analysis on significantly over-expressed genes induced by e-sEV treatment (genes with a fold increase ≥3 
were included). The significant enrichment of TGFβ1-associated pathway was identified. (C) The histogram 
represents the comparison of GO signaling pathways related to genes reported in the Venn diagram and 
Supplementary Tables S3 and S4. Columns represent the % of gene clusters involved in each signaling pathway.
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Figure 7. e-sEVs, but not i-sEVs, induce SMAD1-5 activation and lead to the formation of a SMAD1/5/ID1 
transcriptional complex. (A) Representative SMAD1-5 phosphorylation. ECs treated for the indicated time 
with TGFβ1, e-sEVs and i-sEVs were lysated and analyzed by WB for p-SMAD 1/5, SMAD 1/5 and normalized 
to β-actin content. The results are representative of four different experiments (n = 4) **p < 0.01; ***p < 0.001 
(One-way ANOVA followed by Tukey’s multicomparison test). (B) ChIP analysis of SMAD 1/5 binding to the 
ID1 promoter region using ECs treated for four hours with e-sEVs and i-sEVs and 15 minutes with TGFβ1. RQ 
values of RT-PCR are reported. Selected siRNAs for SMAD1-5 (see Supplementary Fig. S4) were transfected for 
48 hours and ChIP analysis was performed as described above. ECs transfected with duplex siRNAs, alone or 
in combination with e-sEVs, were used as controls. (n = 4) *p < 0.05 C vs TGFβ1 and e-sEVs treatment (One-
way ANOVA followed by Tukey’s multicomparison test). (C) In vitro quantitative analysis of the % of vessel-
like structures formed (tubulogenesis assay) upon siRNA SMAD duplex transfection alone or in combination 
with e-sEVs. (n = 4). **P < 0.01 e-sEVs vs siRNA SMAD1-5 + e-sEVs; ***p < 0.001, C vs e-sEVs, (One-way 
ANOVA followed by Tukey’s multicomparison test).
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assay: negative control was medium w/o FCS; positive control was with 10% FCS; in vitro angiogenesis assay: 
positive control was 10 ng/ml of VEGF). The following formula was applied:
=



−
−



× .effect sample value neg ctrl value
pos ctrl value neg ctrl value
% (0%)
(100%)
100
Values exceeding 50% of VEGF pro-angiogenic capability (for both assays) were considered as making sEVs 
efficient.
In vivo angiogenesis assay. Angiogenesis was assessed as previously described5, 37. Briefly ECs (1 × 106 
cells/injection) were incubated overnight with sEVs (5 × 1010 EVs per 1 × 106 of ECs) and injected subcutane-
ously in severe combined immunodeficiency (SCID) mice. The vessel lumen area was determined as previously 
described5. Details are reported in (Supplementary Information).
Murine model of acute hind limb ischemia and blood flow monitoring. C57 mice (Charles River 
Laboratories), age 7 to 8 weeks were used. Hind limb ischemia was obtained as described19, 31, 65, 66. In preliminary 
experiments, different sEV numbers and e-sEV administration routes were evaluated (not shown). The latter 
included intravenous (iv) and intramuscular (im) alone or differently combined. We found that the best adminis-
tration route and e-sEV number, in terms of animal distress and response to treatment, was 2 × 1010 sEVs: 1 × 1010 
administrated immediately after intervention (T0) iv, 0.5 × 1010 im on day one (T1) and day two (T2). Animals 
were sacrificed on day 7 (T7) for histological analysis. Details are reported in (Online Data Supplement). Hind 
limb blood flow was measured using a Laser Doppler Blood Flow (LDBF) analyzer (PeriScan PIM 3 System, 
Perimed, Stockholm, Sweden), before and after surgery and at days 3 and 7 after surgery as previously described65. 
Details are reported in (Supplementary Information).
In vivo assessment of limb function. Semiquantitative estimation (repeated measures were analyzed with 
ANOVA and Newman-Keuls Multiple Comparison test) of foot damage was performed serially using the fol-
lowing classification: 3 = dragging of foot (foot necrosis), 2 = no dragging but no plantar flexion (foot damage), 
1 = plantar flexion but no toe flexion (toe damage), and 0 = flexing the toes to resist gentle traction on the tail (no 
damage)67.
Evaluation of capillary density and inflammatory cells. Capillary density and inflammatory cells 
were quantified within gastrocnemius muscles using immunofluorescence analysis. Muscle samples were embed-
ded in OCT compound (Bio-Optica) and processed as previously described66. Cryosections of the ischemic limbs 
were stained with rat anti-mouse CD14 primary antibody (PharMingen), while anti-rat Alexa Fluor Texas Red 
(Molecular Probe) was used as secondary antibody. Details are reported in (Supplementary Information).
Histology. The gastrocnemius muscle, from ischemic and non-ischemic limbs, was removed at day 7 
after surgery. Tissue slices were stained with hematoxylin and eosin65. Details are reported in (Supplementary 
Information).
Protein array. Proteins from different sEV preparations were extracted using NP40 lysis buffer (150 mM 
NaCl, 50 mM TRIS-HCl pH 8, 1% NP40) and quantified on a BCA protein assay (Thermo Fisher). The angio-
genic protein profile was performed using Quantibody® Human Angiogenesis array 1000 (Ray Biotech). 25 µg 
of protein were loaded for each sample. Data were expressed as concentration (pg/ml ± SD). Functional annota-
tion enrichment analysis was performed using Funrich V3 software and the geneMANIA plug in on Cytoscape. 
Details are reported in (Supplementary Information).
Western Blot analysis. Proteins from different sEVs and from ECs, treated as indicated were extracted 
using the RIPA buffer (Sigma), then quantified. Thirty µg, for cells, and 10 µg, for EVs, were subjected to WB 
analysis as previously described66. Anti-pser463-465-SMAD1-5 (Cell Signalling), SMAD1/5/9 (abcam), β-actin 
and TGFβ1 (St. Cruz Biotechnology Inc., Santa Cruz, CA) were used. Details are reported in (Supplementary 
Information).
mRNA-angiogenic microarray profile. Total RNA from 4 e-sEV and 4 i-sEV samples was isolated 
using the All in One (Norgen, Thorold, ON, Canada) extraction method. cDNA was synthesized using the RT2 
First Strand kit (SABiosciences) according to manufacturer’s instructions. Gene expression profiling, using the 
Angiogenesis RT2 Profiler PCR Array (PAHS 024, SA Biosciences), was performed on by loading 200 ng of cDNA 
for each sEV sample. The expression profile of 84 key genes in angiogenesis was analyzed (list of genes available 
on website: http://www.sabiosciences.com). Details are reported in (Supplementary Information). The angio-
genesis RT2 Profiler PCR Array was also performed on tubule-like structures formed upon sEV administration 
(n = 6 controls; n = 6 VEGF; n = 4 e-sEVs; n = 4 i-sEVs). Changes in the gene expression of treated, with respect 
to untreated, ECs were reported as a fold increase/decrease ± SD. For e-sEV and i-sEV treatment, up-regulated 
transcripts with a fold increase ≥3 with respect to untreated ECs were used for further investigation. Statistical 
analysis was performed through One-way ANOVA, followed by Tukey’s post hoc or multiple comparison test. 
Data were further analyzed using Expression Suite and Funrich V3 Software. Functional annotation enrichment 
analysis was performed using Funrich V3 software and DAVID GO. Details are reported in (Supplementary 
Information).
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SMAD 1-5 siRNA transfection on ECs. siRNA transfection on ECs was performed using Hiperfect 
Transfection Reagent (Qiagen) according to specific manufacturer’s instructions for ECs. A gene-specific package 
of 4 pre-selected siRNAs for SMAD1 and SMAD5 (Qiagen) were used. Each siRNA targeted a specific sequence 
for SMAD1 (Supplementary Information). The knock-down of SMAD1 and SMAD5 was ascertained by com-
paring RQ values of ECs transfected with duplex siRNAs (negative control) or with siRNA for SMAD1–5 by 
RT-PCR. Silencing was carried out for 48 or 72 hours post-transfection. Details are reported in (Supplementary 
Information).
Chromatin Immunoprecipitation (ChIP) Assay. A ChIP assay was performed on ECs treated with sEVs 
using Magna ChIP A kit (Millipore), according to the vendor’s instructions63. ECs, treated as indicated, were 
cross-linked with 1% formaldehyde and quenched before harvest and sonication. The sheared chromatin was 
immunoprecipitated with either the anti-pser463-465-SMAD1-5 antibody or control IgG on protein G Sepharose 
magnetic beads. The eluted IP were processed as previously described63. Details are reported in (Supplementary 
Information). ChIP analysis was also performed in ECs transfected with siRNAs.
Statistics. Results are expressed as mean ± SD or ± SEM, unless otherwise reported. Statistical analysis was 
carried out using One-way ANOVA, followed by Tukey’s post hoc or multiple comparison, Student t tests for 
2-group comparison and Newman-Keuls Multiple Comparison Test where appropriate. The cut-off for statistical 
significance68, 69 was set at p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001).
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